Aurora Cannabis Focuses On U.K. Medical Cannabis Market, Expands Its Collaboration With Grow Group On Heels Of NASDAQ Transfer

Aurora Inc. (NYSE: ACB) (TSX: ACB) confirmed Thursday its subsidiary Aurora Germany GmbH has extended its collaboration with a United Kingdom-focused biopharmaceutical company Grow Group PLC. The two companies signed a two-year market access services agreement for the U.K.

Previously, the Canadian cannabis giant was one of the first companies to partner with Grow Group in August 2019. Since its original partnership, both companies are said to have dominated the U.K. cannabis market.

"We are delighted to extend our existing strategic relationship with Grow," Miguel Martin, CEO of Aurora Cannabis stated. "We have worked successfully with Grow and their joint venture partner, IPS, since entering the UK market.

“Renewing this agreement will help to broaden access for patients by leveraging Grow's work educating and creating awareness of medical cannabis options. Aurora is committed to providing …

Full story available on Benzinga.com

More Aurora Cannabis Focuses On U.K. Medical Cannabis Market, Expands Its Collaboration With Grow Group On Heels Of NASDAQ Transfer